tesaglitazar has been researched along with bexarotene in 1 studies
| Studies (tesaglitazar) | Trials (tesaglitazar) | Recent Studies (post-2010) (tesaglitazar) | Studies (bexarotene) | Trials (bexarotene) | Recent Studies (post-2010) (bexarotene) |
|---|---|---|---|---|---|
| 74 | 13 | 25 | 642 | 67 | 348 |
| Protein | Taxonomy | tesaglitazar (IC50) | bexarotene (IC50) |
|---|---|---|---|
| Cytochrome P450 3A4 | Homo sapiens (human) | 5.9 | |
| Retinoic acid receptor RXR-alpha | Homo sapiens (human) | 0.632 | |
| Cytochrome P450 26B1 | Homo sapiens (human) | 5.9 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ferrara, SJ; Scanlan, TS | 1 |
1 other study(ies) available for tesaglitazar and bexarotene
| Article | Year |
|---|---|
A CNS-Targeting Prodrug Strategy for Nuclear Receptor Modulators.
Topics: Amides; Amidohydrolases; Animals; Blood-Brain Barrier; Brain; Diffusion; Mice; Mice, Inbred C57BL; Molecular Targeted Therapy; Prodrugs; Receptors, Cytoplasmic and Nuclear; Tissue Distribution | 2020 |